No results for ‘’
Neuland Laboratories Ltd
₹16624
(0.99%)
Wed, 27 May 2026, 10:28 pm
Health Technology
Pharmaceuticals: Major
24.5KNeuland Laboratories Ratios
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 10.63 | 10.14 | 7.36 | 4.13 | 0 | 12.09 | 15.38 | 5.18 | 7.42 | 17.85 | 22.76 | 28.21 | 52.07 | 51.62 | 22.43 | 33.22 | 20.64 | 14.12 | 26.86 | 59.57 |
| Price to book ratio | 1.25 | 1.54 | 1.22 | 0.65 | 0.80 | 0.86 | 0.52 | 0.72 | 1.61 | 1.83 | 3.33 | 2.42 | 1.13 | 1.24 | 0.51 | 3.41 | 1.57 | 2.32 | 6.28 | 10.16 |
| Price to sales ratio | 0.41 | 0.45 | 0.38 | 0.16 | 0.20 | 0.16 | 0.09 | 0.16 | 0.43 | 0.62 | 1.25 | 2.33 | 1.23 | 1.31 | 0.49 | 2.90 | 1.41 | 1.96 | 5.25 | 10.66 |
| Price to cash flow ratio | 7.72 | 0 | 12.28 | 4.44 | 0 | 6.81 | 1.79 | 19.41 | 7.18 | 0 | 21.57 | 74.01 | 0 | 18.29 | 9.43 | 15.43 | 28.08 | 10.20 | 31.52 | 48.47 |
| Enterprise value | 1.01B | 1.61B | 2.08B | 2.38B | 2.75B | 2.83B | 2.57B | 2.84B | 3.88B | 4.66B | 7.94B | 14.94B | 9.23B | 10.35B | 5.73B | 28.35B | 15.34B | 23.78B | 80.37B | 152.85B |
| Enterprise value to EBITDA ratio | 1.45 | 8.46 | 10.05 | 9.34 | 10.48 | 6.31 | 4.93 | 4.63 | 5.30 | 7.13 | 10.12 | 15.53 | 25.14 | 24.15 | 6.84 | 20.62 | 11.88 | 8.83 | 18.02 | 48.69 |
| Debt to equity ratio | 0.79 | 1.31 | 1.95 | 2.64 | 3.41 | 3.17 | 2.89 | 2.14 | 1.53 | 1.16 | 0.98 | 0.35 | 0.57 | 0.33 | 0.37 | 0.23 | 0.29 | 0.13 | 0.07 | 0.10 |
| Return on equity % | 0 | 16.14 | 17.69 | 16.51 | -9.58 | 7.45 | 3.42 | 15.76 | 23.96 | 11.18 | 15.70 | 12.80 | 3.10 | 2.62 | 2.30 | 10.78 | 7.85 | 17.83 | 26.36 | 18.53 |
Neuland Laboratories Ltd Ratios
The Neuland Laboratories Ltd Ratios page provides a complete fundamental analysis of Neuland Laboratories Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Neuland Laboratories Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Neuland Laboratories Ltd (NSE: NEULANDLAB, BSE: 524558) is currently trading at ₹16624, with a market capitalization of ₹215.2B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Neuland Laboratories Ltd remains a key stock for fundamental analysis using Neuland Laboratories Ltd Ratios.
Neuland Laboratories Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Neuland Laboratories Ltd P/E ratio currently stands at 59.57, making it one of the most tracked metrics in Neuland Laboratories Ltd Ratios.
Historically, the Neuland Laboratories Ltd P/E ratio has shown strong fluctuations:
- 2024: 59.57
- 2023: 26.86
- 2022: 14.12
- 2021: 20.64
- 2020: 33.22
The rising Neuland Laboratories Ltd P/E ratio indicates increasing investor confidence and premium valuation.
Price to Book Ratio (P/B)
The Neuland Laboratories Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 10.16.
Historical P/B trend:
- 2024: 10.16
- 2023: 6.28
- 2022: 2.32
- 2021: 1.57
Neuland Laboratories Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Neuland Laboratories Ltd P/S ratio currently stands at 10.66, an important part of Neuland Laboratories Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 10.66
- 2023: 5.25
- 2022: 1.96
- 2021: 1.41
The rising Neuland Laboratories Ltd P/S ratio indicates improved revenue valuation by investors.
Neuland Laboratories Ltd Price to Cash Flow Ratio (P/CF)
The Neuland Laboratories Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 48.47.
Historical Neuland Laboratories Ltd Price to Cash Flow Ratio:
- 2024: 48.47
- 2023: 31.52
- 2022: 10.20
- 2021: 28.08
- 2020: 15.43
The rising Neuland Laboratories Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.
Neuland Laboratories Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Neuland Laboratories Ltd EV currently stands at ₹152.85B, representing the total company valuation including debt.
Historical EV trend:
- 2024: 152.85B
- 2023: 80.37B
- 2022: 23.78B
- 2021: 15.34B
Neuland Laboratories Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.
EV/EBITDA Ratio
The Neuland Laboratories Ltd EV/EBITDA ratio is currently 48.69, a key metric in Neuland Laboratories Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 48.69
- 2023: 18.02
- 2022: 8.83
- 2021: 11.88
Higher Neuland Laboratories Ltd EV/EBITDA suggests premium valuation.
Neuland Laboratories Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Neuland Laboratories Ltd D/E ratio is currently 0.10, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.10
- 2023: 0.07
- 2022: 0.13
- 2021: 0.29
Neuland Laboratories Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Neuland Laboratories Ltd ROE currently stands at 18.53%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 18.53
- 2023: 26.36
- 2022: 17.83
- 2021: 7.85
Neuland Laboratories Ltd maintains stable profitability levels.
Neuland Laboratories Ltd Ratios Analysis Summary
The Neuland Laboratories Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Neuland Laboratories Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Neuland Laboratories Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.